Edwards Lifesciences Corporation Operating Income
Edwards Lifesciences Corporation (EW) reported Operating Income of $513.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- Edwards Lifesciences Corporation operating income (loss) for the quarter ending 2026-06-30 was $513.20M, a 24.81% increase year-over-year.
- Edwards Lifesciences Corporation operating income (loss) for the quarter ending 2026-03-31 was $477.60M, a 20.97% increase year-over-year.
- Edwards Lifesciences Corporation operating income (loss) for the quarter ending 2025-12-31 was $151.10M, a 51.66% decline year-over-year.
- Edwards Lifesciences Corporation operating income (loss) for the quarter ending 2025-09-30 was $307.10M, a 12.41% decline year-over-year.
- Edwards Lifesciences Corporation operating income (loss) for fiscal 2025 was $1.26B, a 8.30% decline from fiscal 2024.
- Edwards Lifesciences Corporation operating income (loss) for fiscal 2024 was $1.38B, a 5.33% increase from fiscal 2023.
- Edwards Lifesciences Corporation operating income (loss) for fiscal 2023 was $1.31B, a 12.65% decline from fiscal 2022.
- Edwards Lifesciences Corporation operating income (loss) for fiscal 2022 was $1.50B, a 11.35% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $513.20M 10-Q · filed 2026-08-04 | $990.80M 10-Q · filed 2026-08-04 | $1.14B derived: sum of 3 quarters · filed 2026-08-04 | $1.45B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $477.60M 10-Q · filed 2026-05-06 | $628.70M derived: sum of 2 quarters · filed 2026-05-06 | $935.80M derived: sum of 3 quarters · filed 2026-05-06 | $1.35B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $151.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $458.20M derived: sum of 2 quarters · filed 2026-02-25 | $869.40M derived: sum of 3 quarters · filed 2026-08-04 | $1.26B 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $307.10M 10-Q · filed 2025-11-05 | $718.30M derived: sum of 2 quarters · filed 2026-08-04 | $1.11B 10-Q · filed 2025-11-05 | $1.43B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $411.20M 10-Q · filed 2026-08-04 | $806.00M 10-Q · filed 2026-08-04 | $1.12B derived: sum of 3 quarters · filed 2026-08-04 | $1.47B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $394.80M 10-Q · filed 2026-05-06 | $707.40M derived: sum of 2 quarters · filed 2026-05-06 | $1.06B derived: sum of 3 quarters · filed 2026-05-06 | $1.42B derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $312.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $663.20M derived: sum of 2 quarters · filed 2026-02-25 | $1.03B derived: sum of 3 quarters · filed 2026-02-25 | $1.38B 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $350.60M 10-Q · filed 2025-11-05 | $717.10M derived: sum of 2 quarters · filed 2025-11-05 | $1.07B 10-Q · filed 2025-11-05 | $1.41B derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $366.50M 10-Q · filed 2025-08-06 | $369.10M 10-Q · filed 2024-07-31 | $715.50M 10-Q · filed 2025-08-06 | $720.20M 10-Q · filed 2024-07-31 | $1.06B derived: sum of 3 quarters · filed 2026-02-25 | $1.43B derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | $349.00M 10-Q · filed 2025-05-06 | $387.50M 10-Q · filed 2024-04-29 | $695.80M derived: sum of 2 quarters · filed 2026-02-25 | $1.06B derived: sum of 3 quarters · filed 2026-02-25 | $1.33B derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | $346.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $712.70M derived: sum of 2 quarters · filed 2026-02-25 | $976.20M derived: sum of 3 quarters · filed 2026-02-25 | $1.31B 10-K · filed 2026-02-25 | $1.53B 10-K · filed 2024-02-12 | |||
| 2023-09-30 | $365.90M 10-Q · filed 2024-11-06 | $418.40M 10-Q · filed 2023-10-27 | $629.40M derived: sum of 2 quarters · filed 2024-11-06 | $962.10M 10-Q · filed 2024-11-06 | $1.13B 10-Q · filed 2023-10-27 | $1.22B derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | $263.50M 10-Q · filed 2024-07-31 | $327.20M 10-Q · filed 2023-07-28 | $601.20M 10-Q · filed 2024-07-31 | $715.60M 10-Q · filed 2023-07-28 | $849.60M derived: sum of 3 quarters · filed 2025-02-28 | $1.25B derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-03-31 | $388.40M 10-Q · filed 2024-04-29 | $586.10M derived: sum of 2 quarters · filed 2025-02-28 | $988.50M derived: sum of 3 quarters · filed 2025-02-28 | $1.45B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $197.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $600.10M derived: sum of 2 quarters · filed 2025-02-28 | $1.06B derived: sum of 3 quarters · filed 2025-02-28 | $1.50B 10-K · filed 2025-02-28 | $1.75B 10-K · filed 2023-02-13 | |||
| 2022-09-30 | $402.40M 10-Q · filed 2023-10-27 | $861.90M derived: sum of 2 quarters · filed 2023-10-27 | $1.30B 10-Q · filed 2023-10-27 | $1.68B derived: sum of 4 quarters · filed 2024-02-12 | ||||
| 2022-06-30 | $459.50M 10-Q · filed 2023-07-28 | $898.30M 10-Q · filed 2023-07-28 | $1.27B derived: sum of 3 quarters · filed 2024-02-12 | $1.66B derived: sum of 4 quarters · filed 2024-02-12 | ||||
| 2022-03-31 | $438.80M 10-Q · filed 2023-04-28 | $813.20M derived: sum of 2 quarters · filed 2024-02-12 | $1.20B derived: sum of 3 quarters · filed 2024-02-12 | $1.75B derived: sum of 4 quarters · filed 2024-02-12 | ||||
| 2021-12-31 | $374.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-12 | $764.70M derived: sum of 2 quarters · filed 2024-02-12 | $1.31B derived: sum of 3 quarters · filed 2024-02-12 | $1.69B 10-K · filed 2024-02-12 | ||||
| 2021-09-30 | $390.30M 10-Q · filed 2022-10-28 | $932.40M derived: sum of 2 quarters · filed 2022-10-28 | $1.32B 10-Q · filed 2022-10-28 | $1.67B derived: sum of 4 quarters · filed 2023-02-13 | ||||
| 2021-06-30 | $542.10M 10-Q · filed 2022-07-29 | $925.60M 10-Q · filed 2022-07-29 | $1.28B derived: sum of 3 quarters · filed 2023-02-13 | $1.63B derived: sum of 4 quarters · filed 2023-02-13 | ||||
| 2021-03-31 | $383.50M 10-Q · filed 2022-04-28 | $734.90M derived: sum of 2 quarters · filed 2023-02-13 | $1.09B derived: sum of 3 quarters · filed 2023-02-13 | $923.00M derived: sum of 4 quarters · filed 2023-02-13 | ||||
| 2020-12-31 | $351.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-13 | $709.20M derived: sum of 2 quarters · filed 2023-02-13 | $539.50M derived: sum of 3 quarters · filed 2023-02-13 | $897.60M 10-K · filed 2023-02-13 | ||||
| 2020-09-30 | $357.80M 10-Q · filed 2021-10-29 | $188.10M derived: sum of 2 quarters · filed 2021-10-29 | $546.20M 10-Q · filed 2021-10-29 | $857.00M derived: sum of 4 quarters · filed 2022-02-14 | ||||
| 2020-06-30 | -$169.70M 10-Q · filed 2021-07-30 | $188.40M 10-Q · filed 2021-07-30 | $499.20M derived: sum of 3 quarters · filed 2022-02-14 | $793.50M derived: sum of 4 quarters · filed 2022-02-14 | ||||
| 2020-03-31 | $358.10M 10-Q · filed 2021-04-28 | $668.90M derived: sum of 2 quarters · filed 2022-02-14 | $963.20M derived: sum of 3 quarters · filed 2022-02-14 | $1.23B derived: sum of 4 quarters · filed 2022-02-14 | ||||
| 2019-12-31 | $310.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-14 | $605.10M derived: sum of 2 quarters · filed 2022-02-14 | $872.60M derived: sum of 3 quarters · filed 2022-02-14 | $1.15B 10-K · filed 2022-02-14 | ||||
| 2019-09-30 | $294.30M 10-Q · filed 2020-10-26 | $561.80M derived: sum of 2 quarters · filed 2020-10-26 | $836.00M 10-Q · filed 2020-10-26 | $830.70M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-06-30 | $267.50M 10-Q · filed 2020-07-27 | $541.70M 10-Q · filed 2020-07-27 | $536.40M derived: sum of 3 quarters · filed 2021-02-12 | $785.30M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-03-31 | $274.20M 10-Q · filed 2020-04-28 | $268.90M derived: sum of 2 quarters · filed 2021-02-12 | $517.80M derived: sum of 3 quarters · filed 2021-02-12 | $769.90M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2018-12-31 | -$5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $243.60M derived: sum of 2 quarters · filed 2021-02-12 | $495.70M derived: sum of 3 quarters · filed 2021-02-12 | $748.20M 10-K · filed 2021-02-12 | ||||
| 2018-09-30 | $248.90M 10-Q · filed 2019-10-25 | $501.00M derived: sum of 2 quarters · filed 2019-10-25 | $753.50M 10-Q · filed 2019-10-25 | $1.09B derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-06-30 | $252.10M 10-Q · filed 2019-07-26 | $504.60M 10-Q · filed 2019-07-26 | $840.70M derived: sum of 3 quarters · filed 2020-02-14 | $1.05B derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-03-31 | $252.50M 10-Q · filed 2019-04-26 | $588.60M derived: sum of 2 quarters · filed 2020-02-14 | $802.60M derived: sum of 3 quarters · filed 2020-02-14 | $1.04B derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2017-12-31 | $336.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $550.10M derived: sum of 2 quarters · filed 2020-02-14 | $791.10M derived: sum of 3 quarters · filed 2020-02-14 | $1.09B 10-K · filed 2020-02-14 | ||||
| 2017-09-30 | $214.00M 10-Q · filed 2018-10-26 | $455.00M derived: sum of 2 quarters · filed 2018-10-26 | $753.30M 10-Q · filed 2018-10-26 | |||||
| 2017-06-30 | $241.00M 10-Q · filed 2018-07-27 | $539.30M 10-Q · filed 2018-07-27 | ||||||
| 2017-03-31 | $298.30M 10-Q · filed 2018-04-27 | |||||||
| 2016-12-31 | $751.20M 10-K · filed 2019-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |